NPT CoTSE:311A 9 ROE % is -278.82% as of Apr. 2025. GuruFocus rates TSE:311A with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 935 Drug Manufacturers companies, NPT Co ranks worse than 94.65% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NPT Co's annualized net income for the quarter that ended in Apr. 2025 was 円-309.93 Mil. NPT Co's average Total Stockholders Equity over the quarter that ended in Apr. 2025 was 円111.16 Mil. Therefore, NPT Co's annualized ROE % for the quarter that ended in Apr. 2025 was -278.82%.
The historical rank and industry rank for NPT Co's ROE % or its related term are showing as below:
TSE:311A'
s ROE % Range Over the Past 10 Years
Min: -447.66 Med: -285.15 Max: -77.15
Current: -77.15
During the past 3 years, NPT Co's highest ROE % was -77.15%. The lowest was -447.66%. And the median was -285.15%.
TSE:311A's ROE % is ranked worse than 94.65% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs TSE:311A: -77.15
NPT Co (TSE:311A) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Apr. 2025) net income data. The Revenue data used here is two times the semi-annual (Apr. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
NPT Co ROE % Related Terms
NPT Co ROE % Historical Data
* Premium members only.
The historical data trend for NPT Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, NPT Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NPT Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NPT Co's ROE % distribution charts can be found below:
* The bar in red indicates where NPT Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Apr. 2025) net income data.
ROE % is displayed in the 30-year financial page.
NPT Co (TSE:311A) has a ROE % of -278.82% as of Apr. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NPT Co and its competitors. According to the industry distribution chart, NPT Co ranks #885 out of 935 companies in the Drug Manufacturers industry, placing it in the top 94.7%.
Is NPT Co's ROE % too high?
NPT Co's current ROE % is -278.82%. Based on the distribution chart, NPT Co ranks #885 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NPT Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does NPT Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NPT Co ranks #885 out of 935 companies for ROE %. This places NPT Co in the lower half of its industry. The industry median ROE % is 6.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NPT Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NPT Co's current ROE % is -278.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NPT Co stock overvalued right now?
NPT Co (TSE:311A) has a current ROE % of -278.82%. The current ROE % is -278.82%. NPT Co's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For NPT Co (TSE:311A), the current ROE % is -278.82% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:311A has been successfully added to your 